India’s Sun Pharma Aims To Buy Controlling Stake In Israel’s Taro Under Merger Pact Options Clause

NEW DELHI - India's Sun Pharma said it will exercise an option to buy 12 percent of Israel-based Taro Pharma held by the founding Levitt family, which includes special voting shares that would give the Mumbai-based firm control to end a disputed merger agreement